Semaglutide Improves eGFR Slope vs. Placebo Regardless of Baseline HbA1c and Blood Pressure in People With Type 2 Diabetes: A Post Hoc Analysis of SUSTAIN 6 and PIONEER 6

被引：0
|
作者：
Cherney, David [1 ]
Bosch-Traberg, Heidrun [2 ]
Hadjadj, Samy [3 ]
Kuhlman, Anja B. [2 ]
Rasmussen, Soren [2 ]
Tuttle, Katherine R. [5 ,6 ]
Heerspink, Hiddo J. L. [4 ]
机构：
[1] Univ Hlth Network, Toronto, ON, Canada
[2] Novo Nordisk, Soborg, Denmark
[3] Inst Thorax, Nantes, France
[4] Univ Med Ctr Groningen, Groningen, Netherlands
[5] Univ Washington, Spokane, WA USA
[6] Providence Washington, Spokane, WA USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2022年 / 33卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
SA-PO265
引用
收藏
页码：675 / 675
页数：1
相关论文
共 50 条
  • [31] A Post Hoc Analysis of HbA1c, Hypoglycemia, and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes
    Bron, Morgan
    Wilson, Craig
    Fleck, Penny
    DIABETES THERAPY, 2014, 5 (02) : 521 - 534
  • [32] Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10
    Matthew Capehorn
    Yasmin Ghani
    Charlotte Hindsberger
    Pierre Johansen
    Esteban Jódar
    Diabetes Therapy, 2020, 11 : 1061 - 1075
  • [33] Efficacy and Safety of Semaglutide 0.5 mg vs. Dulaglutide 1.5 mg Once Weekly in Type 2 Diabetes: A Post Hoc Analysis of SUSTAIN 7
    Pratley, Richard E.
    Aroda, Vanita R.
    Gondolf, Theis
    Hansen, Thomas
    Lingvay, Ildiko
    Luedemann, Joerg
    Skjoeth, Trine Vang
    Viljoen, Adie
    DIABETES, 2019, 68
  • [34] Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
    Leiter, Lawrence A.
    Bain, Stephen C.
    Hramiak, Irene
    Jodar, Esteban
    Madsbad, Sten
    Gondolf, Theis
    Hansen, Thomas
    Holst, Ingrid
    Lingvay, Ildiko
    CARDIOVASCULAR DIABETOLOGY, 2019, 18 (1)
  • [35] Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
    Lawrence A. Leiter
    Stephen C. Bain
    Irene Hramiak
    Esteban Jódar
    Sten Madsbad
    Theis Gondolf
    Thomas Hansen
    Ingrid Holst
    Ildiko Lingvay
    Cardiovascular Diabetology, 18
  • [36] Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10
    Capehorn, Matthew
    Ghani, Yasmin
    Hindsberger, Charlotte
    Johansen, Pierre
    Jodar, Esteban
    DIABETES THERAPY, 2020, 11 (05) : 1061 - 1075
  • [37] The Association Between HbA1c Levels and the Risk of Myocardial Infarction and Stroke in People with Type 2 Diabetes: A Post Hoc Analysis of the REPRESENT Study
    Romera, Irene Cristina
    Redondo-Anton, Jennifer
    Rubio-de Santos, Miriam
    Diaz-Cerezo, Silvia
    Artime, Esther
    Rafels-Ybern, Albert
    Ortega, Emilio
    Conget, Ignacio
    DIABETES THERAPY, 2025,
  • [38] Correlation Between Time in Range and HbA1c in People with Type 2 Diabetes on Basal Insulin: Post Hoc Analysis of the SWITCH PRO Study
    Goldenberg, Ronald M.
    Aroda, Vanita R.
    Billings, Liana K.
    Donatsky, Anders Meller
    Frederiksen, Marie
    Klonoff, David C.
    Kalyanam, Balamurali
    Bergenstal, Richard M.
    DIABETES THERAPY, 2023, 14 (05) : 915 - 924
  • [39] Correlation Between Time in Range and HbA1c in People with Type 2 Diabetes on Basal Insulin: Post Hoc Analysis of the SWITCH PRO Study
    Ronald M. Goldenberg
    Vanita R. Aroda
    Liana K. Billings
    Anders Meller Donatsky
    Marie Frederiksen
    David C. Klonoff
    Balamurali Kalyanam
    Richard M. Bergenstal
    Diabetes Therapy, 2023, 14 : 915 - 924
  • [40] Durable Improvement in HbA1c in Youth-Onset T2D-A Post Hoc Analysis of the DINAMO Trial of Empagliflozin and Linagliptin vs. Placebo
    Laffel, Lori M.
    Danne, Thomas
    Tamborlane, William V.
    Klingensmith, Georgeanna J.
    Neubacher, Dietmar
    Tartakovsky, Igor
    Marquard, Jan
    Zeitler, Philip
    Willi, Steven M.
    DIABETES, 2023, 72
12345